Healthcare -
Drug Manufacturers - Specialty & Generic - NASDAQ - CA
$ 4.975
-2.45 %
$ 273 M
Market Cap
26.18
P/E
1. INTRINSIC VALUE
Balance Sheet
Aurora Cannabis Inc.
| Current Assets | 427 M |
| Cash & Short-Term Investments | 117 M |
| Receivables | 45.4 M |
| Other Current Assets | 264 M |
| Non-Current Assets | 412 M |
| Long-Term Investments | 6.34 M |
| PP&E | 294 M |
| Other Non-Current Assets | 111 M |
| Current Liabilities | 125 M |
| Accounts Payable | 20.3 M |
| Short-Term Debt | 57.2 M |
| Other Current Liabilities | 47.1 M |
| Non-Current Liabilities | 112 M |
| Long-Term Debt | 47.6 M |
| Other Non-Current Liabilities | 64.6 M |
EFFICIENCY
Earnings Waterfall
Aurora Cannabis Inc.
| Revenue | 270 M |
| Cost Of Revenue | 139 M |
| Gross Profit | 131 M |
| Operating Expenses | 159 M |
| Operating Income | -46.5 M |
| Other Expenses | 12.6 M |
| Net Income | -59 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Aurora Cannabis Inc.
| Net Income | -59 M |
| Depreciation & Amortization | 33.1 M |
| Capital Expenditures | -17 M |
| Stock-Based Compensation | 12.7 M |
| Change in Working Capital | -15.6 M |
| Others | -70.7 M |
| Free Cash Flow | -85.5 M |
Wall Street Analysts Price Targets
Aurora Cannabis Inc.
Wall Street analysts predict an average 1-year price target for ACB of $6.67 , with forecasts ranging from
a
low of
$1 to a high of $11 .
ACB Lowest Price Target
Wall Street Target
1 USD
-79.90%
ACB Average Price Target
Wall Street Target
6.67 USD
34.00%
ACB Highest Price Target
Wall Street Target
11 USD
121.11%
4. DIVIDEND
ANALYSIS
ACB does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Aurora Cannabis Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|
7. News
Best Value Stocks to Buy for February 21st
ACB, and PRTH made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 21, 2024.
zacks.com
- 1 week ago
Aurora Cannabis Expands Medical Cannabis Pastille Offerings in Australia
Canada's Leading Medical Cannabis Company Broadens Innovative Product Portfolio to Growing Market in Australia EDMONTON, AB , Feb. 20, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, has announced today the company's extended pastille offerings in Australia. This expansion marks another meaningful step in Aurora's deep commitment to offering patients a diverse range of high-quality, premium medical cannabis products to meet their various needs and interests.
prnewswire.com
- 1 week ago
Breaking Down Barriers: Aurora Cannabis Eases Patient Access to High Quality Medical Cannabis Products in Australia
NASDAQ | TSX: ACB Largest Global Medical Cannabis Company Operating in Nationally Regulated Markets, Aurora Removes Concession Card Requirements to Access IndiMed Products in Australia EDMONTON, AB , Feb. 14, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, in conjunction with MedReleaf Australia, recently removed the concession card requirement for patients to access medical cannabis products under the Company's IndiMed brand. By removing this eligibility barrier, any patient in Australia can now be prescribed IndiMed products, providing greater patient access to high quality medical cannabis options.
prnewswire.com
- 2 weeks ago
Aurora Cannabis Skyrockets After Earnings: Should You Buy Into the Rally?
The year is a more than a month old, but Aurora Cannabis (ACB -2.87%) is already one of the hottest stocks to own in 2025. As of Feb. 11, the pot stock has soared more than 50% since the year began -- and that rally began only a few days ago.
fool.com
- 2 weeks ago
All You Need to Know About Aurora Cannabis (ACB) Rating Upgrade to Strong Buy
Aurora Cannabis (ACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
zacks.com
- 3 weeks ago
Aurora Cannabis: Strong Buy On Blowout Results And Constructive Outlook
Last week, Aurora Cannabis reported blowout Q3/FY2025 results with sales, gross margins, profitability, and free cash flow reaching new all-time highs. As a leader in the medical cannabis space, the company is enjoying premium margins. Following the descheduling of cannabis in Germany last year, sales in Europe have increased substantially. Cash, restricted cash and cash equivalents increased to $180.2 million. The company's core cannabis operations remain debt free.
seekingalpha.com
- 3 weeks ago
3 Marijuana Stocks To Watch As Trading Momentum May Soon Rise
The patience of some marijuana stock investors is still being tested. The public sector for cannabis is a victim of uncertainty and fear in more grey areas. What this means is in the USA there is no federal reform that protects legal operators in any way. Yet states have independently voted to legalize cannabis. From this legal markets are created and legal companies can now produce a federally illegal product.
marijuanastocks.com
- 3 weeks ago
Aurora Cannabis Announces Supply Agreement with SNDL
NASDAQ | TSX: ACB Agreement Complements Existing Relationship Focused on the Supply of Premium Cannabis EDMONTON, AB , February 6, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB) –the Canadian based leading global medical cannabis company, is pleased to announce a strategic supply agreement (the "Agreement") with SNDL Inc. ("SNDL"), a Canadian licensed producer and vertically integrated cannabis enterprise. Under this Agreement, SNDL is expected to supply Aurora with premium cannabis flower product grown at SNDL's indoor facility in Atholville, New Brunswick.
prnewswire.com
- 3 weeks ago
Aurora Cannabis: Remarkable Recovery
Aurora Cannabis has shifted focus to the medical cannabis market, achieving higher gross margins and generating solid cash flows. The company reported FQ3 revenues of C$88 million and a significant improvement in adjusted EBITDA to C$23 million, with free cash flow of C$27 million. ACB stock is trading at just 1x forward sales, presenting a buying opportunity, especially on dips, as the company continues to show financial improvement.
seekingalpha.com
- 3 weeks ago
Aurora Cannabis Inc. (ACB) Q3 2025 Earnings Call Transcript
Aurora Cannabis Inc. (NASDAQ:ACB ) Q3 2025 Earnings Conference Call February 5, 2025 8:00 AM ET Company Participants Kevin Niland - Director of Strategic Finance and Investor Relations Miguel Martin - Chief Executive Officer and Executive Chairman Simona King - Chief Financial Officer Conference Call Participants William Kirk - ROTH Capital Partners Frederico Gomes - ATB Capital Markets Derek Lessard - TD Cowen Matt Bottomley - Canaccord Genuity Douglas Miehm - RBC Capital Markets Operator Greetings and welcome to the Aurora Cannabis Inc. Third Quarter 2025 Results Conference Call. All participants will be in a listen-only mode and a question-and-answer session will follow the formal presentation.
seekingalpha.com
- 3 weeks ago
Aurora Cannabis Inc. (ACB) Surpasses Q3 Earnings and Revenue Estimates
Aurora Cannabis Inc. (ACB) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to loss of $0.20 per share a year ago.
zacks.com
- 3 weeks ago
Aurora Cannabis Stock Jumps On 'Record-Breaking' Q3 Earnings
Canada-based global medical cannabis company Aurora Cannabis Inc ACB reported a third-quarter fiscal 2025 net revenue of CA$88.2 million, compared to CA$64.4 million a year ago.
benzinga.com
- 3 weeks ago
8. Profile
Summary
Aurora Cannabis Inc. ACB
COUNTRY
CA
INDUSTRY
Drug Manufacturers - Specialty & Generic
MARKET CAP
$ 273 M
Dividend Yield
0.00%
Description
Aurora Cannabis Inc. produces, distributes, and sells cannabis and cannabis derivative products in Canada and internationally. It also engages in facility engineering and design, cannabis breeding, research, production, derivatives, product development, wholesale, and retail distribution activities. The company produces various strains of dried cannabis, cannabis oil and capsules, and topical kits for medical patients. It also sells vaporizers; consumable vaporizer accessories; and herb mills for using CanniMed herbal cannabis products, as well as grinders and vaporizer lockable containers. In addition, the company engages in the development of medical cannabis products at various stages of development, including oral, topical, edible, and inhalable products; and operation of CanvasRX, a network of cannabis counseling and outreach centers. Further, it provides patient counselling services; design and construction services; and cannabis analytical product testing services. The company's brand portfolio includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.
Contact
500 - 10355 Jasper Avenue, Edmonton, AB, T5J 1Y6
https://www.auroramj.com
IPO
Date
July 15, 2014
Employees
1073
Officers
Ms. Simona King CPA
Chief Financial Officer
Michelle Lefler
Vice President of Communications & Public Relations
Mr. Ananth Krishnan
Vice President of Capital Markets & Investor Relations
Ms. Lori Schick
Executive Vice President of Human Resources
Mr. Rick Savone
Senior Vice President of Global Government Relations
Mr. Alex Miller
Executive Vice President of Operations & Supply Chain
Mr. Miguel Martin
Chief Executive Officer & Executive Chairman
Ms. Nathalie Clark
Executive Vice President, General Counsel & Corporate Secretary
Mr. Andre Jerome
Executive Vice President of Global Business Development
Dr. Jonathan Page Ph.D.
Senior Science Advisor